Skip to main content

Advertisement

SpringerLink
Log in

The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The prevalence of JAK2V617F tyrosine kinase mutation differs between various variants of myelofibrosis with the higher detection rate for patients with post-polycythemia vera myelofibrosis (post-PV MF; 91%) if compared to primary myelofibrosis (PMF; 45%) and post-essential thrombocythemia myelofibrosis (post-ET MF; 39%). The impact of V617F point mutation and its allele burden on overall survival (OS) and the risk of leukemic transformation (LT) has been the subject of several studies, but the results were ambiguous. Our study included 77 patients with the following variants: 42 patients with PMF (55%), 16 with post-ET MF (21%) and 19 with post-PV MF (24%). Median age at diagnosis for the entire cohort was 61 years (range 19–81), with 53% of female. A total of 42 patients were JAK2V617F positive, giving an overall frequency of 55%; the median allele burden was 22% (range 2–96%). The JAK2V617F point mutation was detected in 21 patients with PMF (50%), 14 with post-PV MF (88%) and 7 with post-ET MF (37%). Lower JAK2V617F allele burden was more frequently detected in PMF patients, whereas higher allele burden was predominantly seen in post-PV/ET MF group. There was no significant difference between V617F-positive and V617F-negative patients in terms of studied parameters in PMF as well as in post-PV/ET MF subgroup. No significant difference was also demonstrated when the above-mentioned subpopulations were analyzed according to JAK2V617F allele burden, except higher leukocyte count in post-PV/ET MF patients with higher allele burden (14.3 × 109/L vs. 6.2 × 109/L; p = .03). Median follow-ups for V617F-positive and V617F-negative patients were 16.6 months (range 3.6–206.4) and 36.4 months (range 2.5–142.1), respectively. The presence of JAK2V617F mutation did not affect OS and the risk of LT development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF(PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31:737–40.

    Article  PubMed  Google Scholar 

  2. Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica. 2003;88:13–8.

    PubMed  Google Scholar 

  3. Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002;118:786–90.

    Article  PubMed  Google Scholar 

  4. Cervantes F, Barosi G. Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging. Semin Oncol. 2005;32:395–402.

    Article  PubMed  Google Scholar 

  5. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013–8.

    PubMed  CAS  Google Scholar 

  6. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.

    PubMed  CAS  Google Scholar 

  7. Tefferi A, Lasho TL, Schwager SM, et al. The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol. 2005;131:320–8.

    Article  PubMed  CAS  Google Scholar 

  8. Campbell PJ, Griesshammer M, Dohner K, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood. 2006;107:2098–100.

    Article  PubMed  CAS  Google Scholar 

  9. Pearson TC, Messinezy M, Westwood N, et al. A Polycythemia vera updated: diagnosis, pathobiology, and treatment. Hematology (Am Soc Hematol Educ Program): 2000; 51–68.

  10. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.

    Article  PubMed  CAS  Google Scholar 

  11. Thiele J, Kvasnicka M. Grade of bone marrow fibrosis is associated with relevant hematological findings: a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol. 2006;85:226–32.

    Article  PubMed  CAS  Google Scholar 

  12. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895–901.

    Article  PubMed  CAS  Google Scholar 

  13. Mitelman F. ISCN. An International System for Human Cytogenetic Nomenclature. Basel: Karger; 1995.

    Google Scholar 

  14. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.

    Article  PubMed  CAS  Google Scholar 

  15. Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007;110:4030–6.

    Article  PubMed  CAS  Google Scholar 

  16. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008;22:756–61.

    Article  PubMed  CAS  Google Scholar 

  17. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood. 2009;114:1477–83.

    Article  PubMed  CAS  Google Scholar 

  18. Tefferi A, Lasho TL, Patnaik MM, et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia. 2010;25:105–9.

    Article  Google Scholar 

  19. Guglielmelli P, Biamonte F, Spolverini A, et al. Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. Leukemia. 2010;24:1533–7.

    Article  PubMed  CAS  Google Scholar 

  20. Guglielmelli P, Barosi G, Pieri L, et al. JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica. 2009;94:144–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Bone Marrow Transplantation, Silesian Medical University, Dabrowski street 25, 40-032, Katowice, Poland

    Grzegorz Helbig, Agata Wieczorkiewicz, Krzysztof Woźniczka, Katarzyna Wiśniewska-Piąty, Anna Rusek & Sławomira Kyrcz-Krzemień

Authors
  1. Grzegorz Helbig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Agata Wieczorkiewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Krzysztof Woźniczka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katarzyna Wiśniewska-Piąty
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anna Rusek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sławomira Kyrcz-Krzemień
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Grzegorz Helbig.

Additional information

Grzegorz Helbig and Agata Wieczorkiewicz have contributed equally in this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Helbig, G., Wieczorkiewicz, A., Woźniczka, K. et al. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis. Med Oncol 29, 2379–2384 (2012). https://doi.org/10.1007/s12032-012-0190-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-012-0190-3

Keywords

Search

Navigation